Vixarelimab 产品活性：Vixarelimab (KPL-716) 是一种人源的抗 oncostatin M (OSM)单克隆抗体，可以与 OSM 受体的β链结合，抑制 IL-31 和 OSM 的信号传导。Vixarelimab 可用于特应性皮炎和结节性痒疹等皮肤炎症性疾病研究。 产品来源： https://www.medchemexpress.cn/vixarelimab.html 研究领域：Immunology/Inflammation 作用靶点：Interleukin Related In Vitro: Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) results in increased MCP-1/CCL2 levels at a concentration of 0.0001 μg/mL in human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF) cells and a significant decrease in MCP-1/CCL2 levels in both cells at concentrations of 0.001 μg/mL or higher. Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) pretreatment results in reduced levels of MCP-1/CCL2 in both Oncostatin M (OSM) induced as well as OSM plus IL-4 induced HEK and HDF cells and the maximum effect is observed at concentrations of 0.01 μg/mL and 0.1 μg/mL. 相关产品：Resatorvid | Disulfiram | Polyinosinic-polycytidylic acid | Raleukin | Deucravacitinib | Dupilumab | Tocilizumab | Apilimod | Oxidopamine hydrobromide | LMT-28 | Theophylline | Secukinumab | Clofazimine | Sodium metatungstate | Benzbromarone | SC144 | Hydrocortisone hemisuccinate | LY3509754 | ODN 2216 | Muscone | Diacerein | JTE-607 | Ixekizumab | APY0201 | Risankizumab | Lysophosphatidylcholines | Ustekinumab | Fibrinogen (Bovine) 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。